Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

KalVista’s Novel DME Approach Moves To Clinical Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

Britain’s KalVista believes it is pioneering the use of kallikrein inhibitors for diabetic macular edema, including orally active derivatives, as it moves its lead compound into U.S. clinical trials.

You may also be interested in...



Deal Watch: Syndax Gets Former Vitae Leukemia Program From Allergan

Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights to its diabetic macular edema candidate, while Arcturus partners with Janssen in hepatitis B.

Genentech Says Lucentis DME Product Will Ship Shortly

FDA approves lower, monthly 0.3 mg dose of injectable Lucentis for diabetic macular edema, the regimen Genentech had suggested was most appropriate. Questions remain about the commercial picture, considering competition from the similar but much cheaper Avastin.

U.K. Ophthalmology Spin-Out Raises £8m For DME Programs

SV Life Sciences and Novo AS support spin-out KalVista with £8m to advance preclinical DME programs.

Topics

Related Companies

UsernamePublicRestriction

Register

PS077588

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel